USD
$0.00
(0.00%
)At Close (As of Oct 24, 2025)
$86.66M
Market Cap
-
P/E Ratio
-3.79
EPS
$6.63
52 Week High
$1.92
52 Week Low
HEALTHCARE
Sector
| Field | Value (USD) |
|---|---|
| Gross Profit | $740K |
| Total Revenue | $1.9M |
| Cost Of Revenue | $1.1M |
| Costof Goods And Services Sold | $1.1M |
| Operating Income | -$61M |
| Selling General And Administrative | $13M |
| Research And Development | $9.8M |
| Operating Expenses | $62M |
| Investment Income Net | - |
| Net Interest Income | -$84K |
| Interest Income | - |
| Interest Expense | $84K |
| Non Interest Income | - |
| Other Non Operating Income | - |
| Depreciation | - |
| Depreciation And Amortization | $1.6M |
| Income Before Tax | -$61M |
| Income Tax Expense | - |
| Interest And Debt Expense | - |
| Net Income From Continuing Operations | -$61M |
| Comprehensive Income Net Of Tax | - |
| Ebit | -$61M |
| Ebitda | -$59M |
| Net Income | -$61M |
| Field | Value (USD) |
|---|---|
| Total Assets | $35M |
| Total Current Assets | $12M |
| Cash And Cash Equivalents At Carrying Value | $8.6M |
| Cash And Short Term Investments | $8.6M |
| Inventory | $410K |
| Current Net Receivables | $1.6M |
| Total Non Current Assets | $23M |
| Property Plant Equipment | - |
| Accumulated Depreciation Amortization Ppe | - |
| Intangible Assets | $15M |
| Intangible Assets Excluding Goodwill | $15M |
| Goodwill | - |
| Investments | - |
| Long Term Investments | - |
| Short Term Investments | - |
| Other Current Assets | $1.1M |
| Other Non Current Assets | - |
| Total Liabilities | $47M |
| Total Current Liabilities | $7.3M |
| Current Accounts Payable | $2.3M |
| Deferred Revenue | - |
| Current Debt | - |
| Short Term Debt | $1.3M |
| Total Non Current Liabilities | $40M |
| Capital Lease Obligations | $3.7M |
| Long Term Debt | - |
| Current Long Term Debt | - |
| Long Term Debt Noncurrent | - |
| Short Long Term Debt Total | $3.7M |
| Other Current Liabilities | $3.7M |
| Other Non Current Liabilities | $38M |
| Total Shareholder Equity | -$12M |
| Treasury Stock | - |
| Retained Earnings | -$351M |
| Common Stock | $338M |
| Common Stock Shares Outstanding | $13M |
| Field | Value (USD) |
|---|---|
| Operating Cashflow | -$21M |
| Payments For Operating Activities | - |
| Proceeds From Operating Activities | - |
| Change In Operating Liabilities | - |
| Change In Operating Assets | - |
| Depreciation Depletion And Amortization | $1.6M |
| Capital Expenditures | $516K |
| Change In Receivables | - |
| Change In Inventory | -$410K |
| Profit Loss | - |
| Cashflow From Investment | -$512K |
| Cashflow From Financing | $20M |
| Proceeds From Repayments Of Short Term Debt | - |
| Payments For Repurchase Of Common Stock | - |
| Payments For Repurchase Of Equity | - |
| Payments For Repurchase Of Preferred Stock | - |
| Dividend Payout | - |
| Dividend Payout Common Stock | - |
| Dividend Payout Preferred Stock | - |
| Proceeds From Issuance Of Common Stock | - |
| Proceeds From Issuance Of Long Term Debt And Capital Securities Net | - |
| Proceeds From Issuance Of Preferred Stock | - |
| Proceeds From Repurchase Of Equity | -$5.4M |
| Proceeds From Sale Of Treasury Stock | - |
| Change In Cash And Cash Equivalents | - |
| Change In Exchange Rate | - |
| Net Income | -$61M |
| Field | Value (USD) |
|---|---|
| Gross Profit | $740K |
| Total Revenue | $1.9M |
| Cost Of Revenue | $1.1M |
| Costof Goods And Services Sold | $1.1M |
| Operating Income | -$61M |
| Selling General And Administrative | $13M |
| Research And Development | $9.8M |
| Operating Expenses | $62M |
| Investment Income Net | - |
| Net Interest Income | -$84K |
| Interest Income | - |
| Interest Expense | $84K |
| Non Interest Income | - |
| Other Non Operating Income | - |
| Depreciation | - |
| Depreciation And Amortization | $1.6M |
| Income Before Tax | -$61M |
| Income Tax Expense | - |
| Interest And Debt Expense | - |
| Net Income From Continuing Operations | -$61M |
| Comprehensive Income Net Of Tax | - |
| Ebit | -$61M |
| Ebitda | -$59M |
| Net Income | -$61M |
Sector: HEALTHCARE
Industry: DIAGNOSTICS & RESEARCH
Insight Molecular Diagnostics Inc. (IMDX) is a leading precision diagnostics company headquartered in Irvine, California, focused on transforming the landscape of molecular testing to improve patient care. The company specializes in developing cutting-edge diagnostic solutions that target critical unmet needs in oncology, leveraging innovative technologies to provide accurate and timely testing results. With a strong commitment to enhancing disease detection and patient outcomes, IMDX is strategically positioned to make a substantial impact in the burgeoning field of personalized medicine, both domestically and internationally.